Edition:
India

INSYS Therapeutics Inc (INSY.OQ)

INSY.OQ on NASDAQ Stock Exchange Global Market

7.74USD
10:17pm IST
Change (% chg)

$-0.02 (-0.26%)
Prev Close
$7.76
Open
$7.79
Day's High
$8.03
Day's Low
$7.71
Volume
69,524
Avg. Vol
132,230
52-wk High
$14.00
52-wk Low
$4.10

Chart for

About

Insys Therapeutics, Inc. is a commercial-stage specialty pharmaceutical company. The Company develops and commercializes supportive care products. The Company's product Subsys, is a sublingual fentanyl spray for breakthrough cancer pain (BTCP) in opioid-tolerant patients and a single-use product that delivers fentanyl, an opioid... (more)

Overall

Beta: 0.85
Market Cap(Mil.): $644.09
Shares Outstanding(Mil.): 72.70
Dividend: --
Yield (%): --

Financials

Florida doctor admits taking kickbacks from Insys, others

June 4 A Florida doctor has admitted, as part of a plea deal, that he received kickbacks from Insys Therapeutics Inc in exchange for writing prescriptions for a powerful fentanyl-based pain medicine.

05 Jun 2018

Minnesota sues opioid maker Insys over improper drug marketing

Minnesota on Wednesday became the latest state to sue Insys Therapeutics Inc , accusing the drugmaker of illegally marketing a powerful fentanyl-based pain medicine, while a former employee pleaded guilty in New Jersey over bribing doctors to prescribe the drug.

31 May 2018

UPDATE 3-Minnesota sues opioid maker Insys over improper drug marketing

May 30 Minnesota on Wednesday became the latest state to sue Insys Therapeutics Inc, accusing the drugmaker of illegally marketing a powerful fentanyl-based pain medicine, while a former employee pleaded guilty in New Jersey over bribing doctors to prescribe the drug.

31 May 2018

Minnesota sues opioid manufacturer Insys over drug marketing

May 30 The state of Minnesota on Wednesday sued Insys Therapeutics Inc, accusing the pharmaceutical manufacturer of illegally marketing a powerful fentanyl-based pain medicine intended for cancer patients for other uses.

30 May 2018

U.S. joins whistleblower case against Insys over kickbacks

The U.S. Department of Justice has joined whistleblower litigation accusing Insys Therapeutics Inc of trying to generate more profit by paying kickbacks to doctors to prescribe powerful opioid medications.

15 May 2018

U.S. joins lawsuits against opioid maker Insys over kickback scheme

May 14 The U.S. Department of Justice has joined lawsuits accusing Insys Therapeutics Inc of paying kickbacks to doctors to prescribe a powerful opioid medication, in an effort to generate more profit.

15 May 2018

BRIEF-Insys Therapeutics Announces Exclusive License Partnership To Commercialize Subsys In Middle East

* INSYS THERAPEUTICS ANNOUNCES EXCLUSIVE LICENSE PARTNERSHIP WITH LUNATUS TO COMMERCIALIZE SUBSYS® (FENTANYL SUBLINGUAL SPRAY) IN THE MIDDLE EAST

09 May 2018

BRIEF-Insys Therapeutics Reports First Quarter 2018 Results

* Q1 EARNINGS PER SHARE VIEW $-0.18 -- THOMSON REUTERS I/B/E/S

09 May 2018

Ex-Insys employee in U.S. opioid case sentenced to home confinement

April 23 A former Insys Therapeutics Inc sales representative was sentenced on Monday to six months of home confinement after admitting that she participated in a scheme to pay kickbacks to two Alabama doctors to prescribe a fentanyl-based medication.

24 Apr 2018

BRIEF-Insys Therapeutics To Advance Clinical Research Of Dronabinol Inhalation Using Novel Breath-Actuated Device

* INSYS THERAPEUTICS TO ADVANCE CLINICAL RESEARCH OF DRONABINOL INHALATION USING NOVEL BREATH-ACTUATED DEVICE

18 Apr 2018

Earnings vs. Estimates